Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Alzheimer's disease.

Blennow K, de Leon MJ, Zetterberg H.

Lancet. 2006 Jul 29;368(9533):387-403. Review.

PMID:
16876668
2.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

4.

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H.

BMJ. 2005 Aug 6;331(7512):321-7. Review.

5.
6.

Alzheimer disease and its management: a review.

Samanta MK, Wilson B, Santhi K, Kumar KP, Suresh B.

Am J Ther. 2006 Nov-Dec;13(6):516-26. Review.

PMID:
17122533
7.

New drugs for Alzheimer's disease in Japan.

Takeda M, Tanaka T, Okochi M.

Psychiatry Clin Neurosci. 2011 Aug;65(5):399-404. doi: 10.1111/j.1440-1819.2011.02253.x. Review. No abstract available.

8.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
9.

Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.

Musiał A, Bajda M, Malawska B.

Curr Med Chem. 2007;14(25):2654-79. Review.

PMID:
17979717
10.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. Review.

PMID:
16323253
11.

Switching cholinesterase inhibitors in older adults with dementia.

Massoud F, Desmarais JE, Gauthier S.

Int Psychogeriatr. 2011 Apr;23(3):372-8. doi: 10.1017/S1041610210001985. Epub 2010 Nov 3. Review.

PMID:
21044399
12.

[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].

Shoji M.

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):630-6. Review. Japanese. No abstract available.

PMID:
24796129
13.

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.

Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.

J Alzheimers Dis. 2013;35(2):349-61. doi: 10.3233/JAD-122140. Review.

PMID:
23411693
14.

[Medical treatment of Alzheimer's disease].

Johannsen P.

Ugeskr Laeger. 2006 Oct 2;168(40):3424-9. Review. Danish.

PMID:
17032609
15.

Evidence-based pharmacotherapy of Alzheimer's disease.

Evans JG, Wilcock G, Birks J.

Int J Neuropsychopharmacol. 2004 Sep;7(3):351-69. Epub 2004 Jul 1. Review.

PMID:
15228642
16.

Acetylcholinesterase inhibition in Alzheimer's Disease.

Ibach B, Haen E.

Curr Pharm Des. 2004;10(3):231-51. Review.

PMID:
14754384
17.

Alzheimer's disease and amyloid: culprit or coincidence?

Skaper SD.

Int Rev Neurobiol. 2012;102:277-316. doi: 10.1016/B978-0-12-386986-9.00011-9. Review.

PMID:
22748834
18.

Current treatments for Alzheimer's disease: cholinesterase inhibitors.

Doody RS.

J Clin Psychiatry. 2003;64 Suppl 9:11-7. Review.

19.

The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?

Khang P, Weintraub N, Espinoza RT.

J Am Med Dir Assoc. 2004 Jul-Aug;5(4):249-55. Review. No abstract available.

PMID:
15228635
20.

Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.

Götz J, Schild A, Hoerndli F, Pennanen L.

Int J Dev Neurosci. 2004 Nov;22(7):453-65. Review.

PMID:
15465275
Items per page

Supplemental Content

Write to the Help Desk